UMB FINANCIAL CORP
For the period ended Sep 30, 2025. Filed Oct 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 30, 2025
UMBF$135.86-0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED STATEMENTS OF INCOME
(unaudited, dollars in thousands, except share and per share data)
| Three Months Ended · Nine Months Ended | ||||
|---|---|---|---|---|
| September 30, | September 30, | |||
| 2025 | 2024 | 2025 | 2024 | |
| INTEREST INCOME | ||||
| Loans | $629,057 | $416,400 | $1,768,875 | $1,202,317 |
| Securities: | ||||
| Taxable interest | 138,176 | 63,466 | 358,709 | 186,159 |
| Tax-exempt interest | 33,035 | 24,578 | 96,022 | 74,988 |
| Total securities income | 171,211 | 88,044 | 454,731 | 261,147 |
| Federal funds and resell agreements | 9,365 | 4,990 | 25,050 | 11,726 |
| Interest-bearing due from banks | 68,952 | 47,969 | 217,811 | 139,831 |
| Trading securities | 312 | 291 | 937 | 1,020 |
| Total interest income | 878,897 | 557,694 | 2,467,404 | 1,616,041 |
| INTEREST EXPENSE | ||||
| Deposits | 362,882 | 262,599 | 1,009,441 | 726,999 |
| Federal funds and repurchase agreements | 28,632 | 27,070 | 81,845 | 82,813 |
| Other | 12,341 | 20,649 | 36,413 | 74,311 |
| Total interest expense | 403,855 | 310,318 | 1,127,699 | 884,123 |
| Net interest income | 475,042 | 247,376 | 1,339,705 | 731,918 |
| Provision for credit losses | 22,500 | 18,000 | 129,500 | 42,050 |
| Net interest income after provision for credit losses | 452,542 | 229,376 | 1,210,205 | 689,868 |
| NONINTEREST INCOME | ||||
| Trust and securities processing | 87,926 | 74,222 | 250,970 | 213,710 |
| Trading and investment banking | 7,026 | 7,118 | 19,107 | 18,041 |
| Service charges on deposit accounts | 29,150 | 20,089 | 85,472 | 63,107 |
| Insurance fees and commissions | 307 | 282 | 674 | 832 |
| Brokerage fees | 20,470 | 15,749 | 59,097 | 42,929 |
| Bankcard fees | 29,561 | 22,394 | 84,872 | 66,708 |
| Investment securities (losses) gains, net | (4,093) | 2,623 | 28,810 | 10,127 |
| Other | 32,951 | 16,266 | 62,679 | 47,452 |
| Total noninterest income | 203,298 | 158,743 | 591,681 | 462,906 |
| NONINTEREST EXPENSE | ||||
| Salaries and employee benefits | 220,329 | 146,984 | 655,278 | 432,851 |
| Occupancy, net | 19,149 | 12,274 | 53,789 | 36,267 |
| Equipment | 16,563 | 15,988 | 49,937 | 48,094 |
| Supplies and services | 10,492 | 4,967 | 21,660 | 11,672 |
| Marketing and business development | 11,094 | 6,817 | 30,436 | 19,440 |
| Processing fees | 45,008 | 29,697 | 129,496 | 87,334 |
| Legal and consulting | 21,616 | 9,518 | 68,690 | 33,978 |
| Bankcard | 11,775 | 12,482 | 36,933 | 34,867 |
| Amortization of other intangible assets | 25,317 | 1,917 | 68,067 | 5,788 |
| Regulatory fees | 8,091 | 4,686 | 25,587 | 26,649 |
| Other | 29,851 | 7,124 | 57,367 | 19,385 |
| Total noninterest expense | 419,285 | 252,454 | 1,197,240 | 756,325 |
| Income before income taxes | 236,555 | 135,665 | 604,646 | 396,449 |
| Income tax expense | 48,239 | 26,022 | 117,603 | 75,203 |
| NET INCOME | $188,316 | $109,643 | $487,043 | $321,246 |
| Less: Preferred dividends | 7,944 | — | 11,969 | — |
| NET INCOME AVAILABLE TO COMMON SHAREHOLDERS | $180,372 | $109,643 | $475,074 | $321,246 |
| PER SHARE DATA | ||||
| Net income per common share – basic | $2.38 | $2.25 | $6.57 | $6.59 |
| Net income per common share – diluted | 2.36 | 2.23 | 6.53 | 6.56 |
| Dividends per common share | 0.40 | 0.39 | 1.20 | 1.17 |
| Weighted average common shares outstanding – basic | 75,943,943 | 48,775,072 | 72,349,952 | 48,727,914 |
| Weighted average common shares outstanding – diluted | 76,366,818 | 49,078,497 | 72,744,289 | 48,993,581 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.